Ghassan K. Abou-Alfa, MD, a medical oncologist at Memorial Sloan Kettering Cancer Center, discusses tiselizumab’s mechanism of action in patients with hepatocellular carcinoma.
Ghassan K. Abou-Alfa, MD, a medical oncologist at Memorial Sloan Kettering Cancer Center, discusses tiselizumab’s mechanism of action in patients with hepatocellular carcinoma (HCC).
Tiselizumab is an investigational anti-PD1 monoclonal antibody, according to Abou-Alfa. It has a high affinity for PD-1 due to the fact it’s designed to minimize the bindings of FC gamma receptors to microphages. This process limits antibody-dependent phagocytosis.
This allows T cells to come into full play, says Abou-Alfa. However, due to the FC gamma receptors, this may be a more laborious process. With the extra assets provided by tiselizumab, some of the challenges may be alleviated, according to Abou-Alfa.
Gholam Analyzes Treatment Outcomes for Advanced HCC in Child-Pugh B Population
April 28th 2024During a live Community Case Forum event in partnership with the Tennessee Oncology Practice Society, Pierre Gholam, MD, examined the current state of treatment for patients with hepatocellular carcinoma, looking in particular at what data is available for those with Child-Pugh B and C status who have poorer outcomes and have limited data from prospective clinical trials.
Read More